Pharma

Pharmalot Ed Silverman

STAT Plus: J&J agrees not to enforce patents on a key tuberculosis drug in dozens of poor countries

Politics Rachel Cohrs

STAT Plus: Court allows Medicare drug price negotiation to proceed

Pharmalot Ed Silverman

STAT Plus: Unitaid slams J&J over pricing and patents for a tuberculosis drug

Pharmalot Ed Silverman

STAT Plus: Generic makers fall short when providing access to low- and middle-income countries, analysis finds

Pharmalot Ed Silverman

STAT Plus: Sales from controversial drug discount program rose to $54 billion last year

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Deadline looms for drugmakers to negotiate with Medicare; GOP senator probes 340B program at two hospitals

Politics John Wilkerson

STAT Plus: GOP senator probes drug discount programs at Cleveland Clinic, Bon Secours

Pharmalot Ed Silverman

STAT Plus: Drug industry payments to eye docs boosted Medicare spending on pricier treatments

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA advisers vote overwhelmingly against ALS treatment; weight-loss drugs scrutinized over reports of suicidal thoughts

Politics John Wilkerson

STAT Plus: 6 ways the government could help address drug shortages, including in cancer

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Pharma would lose loyal ally if Menendez leaves Senate; EMA to discuss anesthesia risk for weight-loss drugs

Pharma Annalisa Merelli

STAT Plus: Just how much money do drugmakers gain from patent extensions?

Politics Sarah Owermohle

STAT Plus: With Menendez indictment, pharmaceutical industry could lose a key ally

D.C. Diagnosis Sarah Owermohle

STAT Plus: Will a government shutdown stall Medicare drug price negotiations?

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA to furlough one-fifth of staff if government shuts down; FDA cites ‘grossly deficient’ data for ALS drug

Pharmalot Jonathan Wosen

STAT Plus: Pharmalittle: End of biotech’s stock market malaise may be near; cancer drug shortages hit rural clinics hard

Pharmalot Ed Silverman

STAT Plus: Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: FDA finds problems at Novo’s main U.S. factory; polarizing ALS drug heads for FDA scrutiny

Pharma Annalisa Merelli

STAT Plus: Approval setback for EpiPen alternative puts spotlight on common anti-competition tactic

Pharmalot Ed Silverman

STAT Plus: Novartis is scolded by U.K. trade group for the fourth time this year over Entresto promotions

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback

Pharmalot Ed Silverman

STAT Plus: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro

Pharmalot Ed Silverman

STAT Plus: How a cash-prize system that phases out patents may lower drug prices

Politics John Wilkerson

STAT Plus: PBMs were the target of House hearing, but pharma wasn’t spared criticism

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: Cepheid agrees to sell a TB test at cost; Mallinckrodt weighs selling some or all businesses

Pharmalot Ed Silverman

STAT Plus: After a high-profile pressure campaign, Cepheid agrees to sell a TB test at cost

Pharmalot Ed Silverman

STAT Plus: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing